TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25830321

Group type: EXPERIMENTAL
Intervention: cfDNA testing
Number of subjects: 15841

Group type: COMPARATOR
Intervention: Standard screening
Number of subjects: 15841
Study: 25830416

Group type: EXPERIMENTAL
Intervention: Variable cluster sizes
Number of subjects: 0
Study: 25831265

Group type: EXPERIMENTAL
Intervention: SBIRT eHealth tool
Number of subjects: 200
Study: 25832001

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN-α) treatment
Number of subjects: 275

Group type: COMPARATOR
Intervention: Non-treated patients
Number of subjects: 275
Study: 25832466

Group type: EXPERIMENTAL
Intervention: BMTP-11
Number of subjects: 0
Study: 25833388

Group type: EXPERIMENTAL
Intervention: Postoperative anesthetic handovers using a detailed checklist of 55 items.
Number of subjects: 441
Study: 25833390

Group type: EXPERIMENTAL
Intervention: Bortezomib in combination with ifosfamide and vinorelbine (IVB)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 26
Study: 25833826

Group type: EXPERIMENTAL
Intervention: Zinc and selenium supplementation at physiological concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher concentrations of zinc and selenium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control patients without sepsis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with sepsis
Number of subjects: 0
Study: 25833956

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study: 25833968

Group type: EXPERIMENTAL
Intervention: Satiation (eating a meal to satiation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fasted state (not eating for 4 hours)
Number of subjects: 16
Study: 25833973

Group type: EXPERIMENTAL
Intervention: Fat-Free Mass Index (FFMI) in quartiles 3 and 4
Number of subjects: 3181

Group type: EXPERIMENTAL
Intervention: Fat-Free Mass Index (FFMI) in quartile 4 (>19.5 kg/m²)
Number of subjects: 3181

Group type: COMPARATOR
Intervention: Body composition (FMI and FFMI)
Number of subjects: 3181

Group type: COMPARATOR
Intervention: Body Mass Index (BMI)
Number of subjects: 3181
Study: 25833975

Group type: EXPERIMENTAL
Intervention: Total dairy intake
Number of subjects: 10010

Group type: EXPERIMENTAL
Intervention: Fermented dairy products
Number of subjects: 10010
Study: 25834212

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg every other week for up to 12 weeks or 20 weeks
Number of subjects: 268
Study: 25834952

Group type: EXPERIMENTAL
Intervention: Maternal plasma DNA testing
Number of subjects: 1700000

Group type: COMPARATOR
Intervention: Serum-based screening
Number of subjects: 1700000
Study: 25837499

Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lenalidomide 20 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 intravenously (days 1, 8, and 15)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) as prophylactic anticoagulant
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Overall treatment-related adverse events (AEs)
Number of subjects: 12
Study: 25837513

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine
Number of subjects: 0
Study: 25837801

Group type: EXPERIMENTAL
Intervention: Early levosimendan administration (perioperatively up to the first hour after ICU admission)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Late levosimendan administration (later than the first hour after ICU admission)
Number of subjects: 159
Study: 25838266

Group type: EXPERIMENTAL
Intervention: H7N7 IIV after priming with H7N7 LAIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: H7N7 IIV
Number of subjects: 0
Study: 25839931

Group type: EXPERIMENTAL
Intervention: Use of nasal splints
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Presence of sinusitis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Advancing age
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Use of absorbable nasal packing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Health status (multidimensional QOL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Time to resolution of nasal crusting
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Time to resolution of mucopurulence
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Time to resolution of synechia
Number of subjects: 100
Study: 25840034

Group type: EXPERIMENTAL
Intervention: hs-cTnI 1h-algorithm
Number of subjects: 1811
Study: 25840428

Group type: EXPERIMENTAL
Intervention: Women with PCOS who developed GDM
Number of subjects: 72

Group type: COMPARATOR
Intervention: Women with PCOS who did not develop GDM
Number of subjects: 72
Study: 25840600

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25840640

Group type: EXPERIMENTAL
Intervention: Speckle-tracking echocardiography
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: RV fractional area change
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Inferolateral strain
Number of subjects: 135

Group type: COMPARATOR
Intervention: Conventional echocardiographic parameters
Number of subjects: 135
Study: 25840829

Group type: EXPERIMENTAL
Intervention: Intensive Short-term Dynamic Psychotherapy (ISTDP), average of 7.3 sessions
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Control group (patients referred but never treated)
Number of subjects: 1082
Study: 25840894

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging with dual-focus (NBI-DF)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard imaging techniques (white light)
Number of subjects: 270
Study: 25841330

Group type: EXPERIMENTAL
Intervention: Basophil activation testing
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: sIgE
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: sIgE/sIgG4 ratio
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ara h 2 IgE
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ara h 8 IgE
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: SPT
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: tIgE
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: sIgG4
Number of subjects: 67
Study: 25841541

Group type: EXPERIMENTAL
Intervention: Bone Mineral Content (BMC)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Osteocalcin (OCN)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor 23 (FGF23)
Number of subjects: 37
Study: 25841875

Group type: EXPERIMENTAL
Intervention: aMMP-8 test
Number of subjects: 60
Study: 25844160

Group type: EXPERIMENTAL
Intervention: 12-week PATCH intervention + usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 25846031

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (≤ 14 mg/24 h; dose adjustments ≤ 16 mg/24 h permitted)
Number of subjects: 87
Study: 25846669

Group type: EXPERIMENTAL
Intervention: Intratumoral TG1042 injection (adenovirus expressing IFN-γ) combined with tumor-infiltrating lymphocytes (TILs)
Number of subjects: 18
Study: 25847227

Group type: EXPERIMENTAL
Intervention: Glass-based yttrium 90 therapy
Number of subjects: 30
Study: 25847808

Group type: EXPERIMENTAL
Intervention: Assault-injury group (AIG)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Comparison group (CG)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: AIG
Number of subjects: 349
Study: 25847929

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m(2) IV on days 1 and 8), Carboplatin (AUC 2 IV on days 1 and 8), Iniparib (5.6 mg/kg IV on days 1, 4, 8, and 11) administered every 21 days for four cycles (amended to six cycles).
Number of subjects: 80
Study: 25847936

Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m(2) every 3 weeks)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 6 every 3 weeks)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: BRCA-like genomic instability signature
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: p63/p73 expression status
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: p53 and PIK3CA mutation status
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: PAM50 gene expression subtype
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Long-term responders
Number of subjects: 86
Study: 25848412

Group type: EXPERIMENTAL
Intervention: Electronic Health Records (EHRs)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Paper records
Number of subjects: 328
Study: 25848948

Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C (IVC) combined with chemotherapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-dose intravenous vitamin C (IVC)
Number of subjects: 14
Study: 25849228

Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment
Number of subjects: 42
Study: 25849571

Group type: EXPERIMENTAL
Intervention: Serum concentrations of sulfur-containing amino acids (SAAs), especially taurine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Serum concentrations of cystine, taurine, and SAA levels
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores
Number of subjects: 35
Study: 25849721

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times daily for ≥2 weeks
Number of subjects: 39
Study: 25850031

Group type: EXPERIMENTAL
Intervention: CHL1 rs4003413
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: GAP43 rs283393 and rs9860828
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: ITGB3 rs3809865
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: GAP43 molecular pathway
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: ELAVL4
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: ITGB1 and NRP1
Number of subjects: 459
Study: 25851633

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgrastim (crossover from placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgrastim/Pegfilgrastim
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G-CSF primary prophylaxis
Number of subjects: 0
Study: 25852054

Group type: EXPERIMENTAL
Intervention: CMV reactivation
Number of subjects: 0
Study: 25852166

Group type: EXPERIMENTAL
Intervention: Weight loss after bariatric surgery (1 year post-surgery)
Number of subjects: 12
Study: 25852820

Group type: EXPERIMENTAL
Intervention: Adjuvant Adriamycin-based chemotherapy with increased BFI scores (32 patients)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (11 patients without increased BFI scores)
Number of subjects: 43
Study: 25852948

Group type: EXPERIMENTAL
Intervention: No-touch (NT) vein graft
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional (C) vein graft
Number of subjects: 65
Study: 25852962

Group type: EXPERIMENTAL
Intervention: End-tidal CO2 (EtCO2) monitoring using a dedicated naso-buccal sensor during non-invasive ventilation (NIV)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Active and passive prolonged expiratory maneuvers
Number of subjects: 11
Study: 25853713

Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure (COP) in plasma
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure (COP) in interstitial fluid
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: COP in interstitial fluid sampled from arm and leg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Effect of prolonged implantation time on interstitial COP
Number of subjects: 99
Study: 25853747

Group type: EXPERIMENTAL
Intervention: Ibrutinib at a daily dose of 420 mg
Number of subjects: 63
Study: 25853841

Group type: EXPERIMENTAL
Intervention: CAVI measurement
Number of subjects: 110
Study: 25853929

Group type: EXPERIMENTAL
Intervention: Biodegradable biliary stent (BDBS) insertion via endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 1
Study: 25855120

Group type: EXPERIMENTAL
Intervention: δ(13)C value of finger-stick blood
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Dual-isotope model (δ(13)C and δ(15)N)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Nonsweetener corn intake
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: δ(15)N value
Number of subjects: 257
Study: 25855376

Group type: EXPERIMENTAL
Intervention: Prophylaxis (recombinant FVIII-FS 20-30 IU/kg thrice weekly)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 58
Study: 25855621

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, oral) until disease progression, intolerable toxicity or death
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, oral) in non-smokers with adenocarcinoma
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, oral)
Number of subjects: 519
Study: 25855668

Group type: EXPERIMENTAL
Intervention: PA:A>1 group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RV dysfunction and PA enlargement
Number of subjects: 24
Study: 25855677

Group type: EXPERIMENTAL
Intervention: Micra Transcatheter Pacing System
Number of subjects: 720
Study: 25856269

Group type: EXPERIMENTAL
Intervention: Catheter-directed therapy (CDT) with low-dose hourly infusion of tissue plasminogen activator (tPA) or urokinase; average doses were 28.0 ± 11 mg tPA (n = 76) and 2,697,101 ± 936,287 International Units for urokinase (n = 23).
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Catheter-directed therapy (CDT)
Number of subjects: 101
Study: 25856364

Group type: EXPERIMENTAL
Intervention: PAC-1 analogues
Number of subjects: 0

Group type: COMPARATOR
Intervention: PAC-1
Number of subjects: 0
Study: 25856540

Group type: EXPERIMENTAL
Intervention: Sleep apnea risk
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Short sleep duration
Number of subjects: 1013
Study: 25856546

Group type: EXPERIMENTAL
Intervention: botulinum toxin-A (BoNT-A) treatment
Number of subjects: 456
Study: 25857307

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 39
Study: 25858004

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25858045

Group type: EXPERIMENTAL
Intervention: 1-d imaging protocol (3.7-7.4 MBq/kg, followed by 11.1 MBq/kg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 2-d protocol (7.4 MBq/kg for both rest and stress)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 1-d and 2-d protocols
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 1-d imaging protocol
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 2-d protocol
Number of subjects: 78
Study: 25858498

Group type: EXPERIMENTAL
Intervention: Cixutumumab 1 mg/kg, 3 mg/kg, or 6 mg/kg intravenously on days 1/8/15 with doxorubicin 75 mg/m² as a 48 h infusion on day 1 of a 21 day cycle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cixutumumab alone after six cycles of combination therapy
Number of subjects: 30
Study: 25858519

Group type: EXPERIMENTAL
Intervention: Long-term omeprazole therapy
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Long-term esomeprazole therapy
Number of subjects: 812

Group type: COMPARATOR
Intervention: Anti-reflux surgery (ARS)
Number of subjects: 812
Study: 25858543

Group type: EXPERIMENTAL
Intervention: Laparoscopic diaphragm biopsy technique
Number of subjects: 51

Group type: COMPARATOR
Intervention: Electrocoagulation biopsies
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Laparoscopic diaphragm biopsy without electrocoagulation
Number of subjects: 51
Study: 25858546

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone ablation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) correlation
Number of subjects: 0
Study: 25858957

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25859981

Group type: EXPERIMENTAL
Intervention: Voxel-based parametric response maps (PRM) of diffusion-weighted MRI and CT scans
Number of subjects: 0
Study: 25860107

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 to 200 mg/day
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 798

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study: 25860203

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy administered by a specialized pediatric transport team
Number of subjects: 235
Study: 25861036

Group type: EXPERIMENTAL
Intervention: Motor Function Measure, MyoGrip, MyoPinch, MoviPlate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MyoGrip, MyoPinch, MoviPlate
Number of subjects: 23
Study: 25861217

Group type: EXPERIMENTAL
Intervention: Treatment selected to target a somatic mutation in the tumor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study: 25861285

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 25861459

Group type: EXPERIMENTAL
Intervention: ISM-High
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISM-Low
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 0
Study: 25862255

Group type: EXPERIMENTAL
Intervention: Short Performance Physical Battery
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Timed Up and Go test
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Number of subjects: 244
Study: 25862507

Group type: EXPERIMENTAL
Intervention: Aligned Group (AG)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Malaligned Group (MG)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 25862508

Group type: EXPERIMENTAL
Intervention: Trunk motor control in patients with acute to subacute LBP (eyes-closed condition)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Movement precision in patients with acute to subacute LBP
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Self-reported pain characteristics and fear of movement in patients with acute to subacute LBP
Number of subjects: 33
Study: 25862561

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS)-MRD
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Post-HCT NGS-MRD
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Any post-HCT NGS positivity
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Absence of detectable IgH-V(D)J NGS-MRD pre-HCT
Number of subjects: 56
Study: 25862716

Group type: EXPERIMENTAL
Intervention: Left Atrial (LA) strain at atrial contraction (LASac)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Left Atrial Volume (LAV)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Septal Electromechanical Conduction Time
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Combination of LASac and Systolic Blood Pressure
Number of subjects: 146
Study: 25864160

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of 45 CAD risk variants
Number of subjects: 6041

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of 45 CAD risk variants in men
Number of subjects: 6041

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of 45 CAD risk variants in individuals above median age of 45.11 years
Number of subjects: 6041
Study: 25864295

Group type: EXPERIMENTAL
Intervention: Laronidase enzyme replacement therapy (ERT)
Number of subjects: 1
Study: 25865468

Group type: EXPERIMENTAL
Intervention: Gliovac (ERC 1671) administered intradermally with human GM-CSF (Leukine(®)), preceded by low-dose cyclophosphamide regimen.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (standard of care treatment).
Number of subjects: 9
Study: 25867467

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (44 μg subcutaneously three times weekly)
Number of subjects: 23
Study: 25867537

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) reported at visit 1
Number of subjects: 838
Study: 25867642

Group type: EXPERIMENTAL
Intervention: Group-based psycho-educational HIV/STI intervention
Number of subjects: 44
Study: 25869032

Group type: EXPERIMENTAL
Intervention: High-speed Video-Microscopy Analysis (HVMA)
Number of subjects: 203
Study: 25869198

Group type: EXPERIMENTAL
Intervention: Cheatham Platinum stent
Number of subjects: 105
Study: 25869350

Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: CACS (threshold of 400)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Hybrid (CACS/SPECT)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Hybrid (coronary CTA/SPECT)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: CACS (threshold 400)
Number of subjects: 138
Study: 25869737

Group type: EXPERIMENTAL
Intervention: Gas chromatography linked to mass spectrometry (GCMS)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Cross-reactive nanoarrays combined with pattern recognition
Number of subjects: 484
Study: 25869867

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T 1-hour algorithm
Number of subjects: 1320
Study: 25870087

Group type: EXPERIMENTAL
Intervention: AUY922 (70 mg) and erlotinib (150 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: AUY922 and erlotinib (doses not specified for phase II)
Number of subjects: 37